BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30248389)

  • 1. Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey.
    Hardiansyah D; Ng CM
    Eur J Pharm Sci; 2018 Dec; 125():130-141. PubMed ID: 30248389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.
    Ng CM; Fielder PJ; Jin J; Deng R
    AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.
    Hardiansyah D; Ng CM
    MAbs; 2018 Oct; 10(7):1144-1156. PubMed ID: 29969360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.
    Yuan D; Rode F; Cao Y
    AAPS J; 2018 Mar; 20(3):48. PubMed ID: 29541870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley Rats.
    Hardiansyah D; Ng CM
    Pharm Res; 2022 Mar; 39(3):481-496. PubMed ID: 35246757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
    Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
    Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life.
    Yeung YA; Wu X; Reyes AE; Vernes JM; Lien S; Lowe J; Maia M; Forrest WF; Meng YG; Damico LA; Ferrara N; Lowman HB
    Cancer Res; 2010 Apr; 70(8):3269-77. PubMed ID: 20354184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.
    Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Wroblewski VJ
    J Biol Chem; 2007 Jan; 282(3):1709-17. PubMed ID: 17135257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
    Shah DK; Betts AM
    J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of K
    Maas BM; Cao Y
    MAbs; 2018; 10(8):1322-1331. PubMed ID: 30130450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans.
    Hardiansyah D; Ng CM
    Pharm Res; 2018 Feb; 35(3):47. PubMed ID: 29411151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium.
    Dithmer M; Hattermann K; Pomarius P; Aboul Naga SH; Meyer T; Mentlein R; Roider J; Klettner A
    Exp Eye Res; 2016 Apr; 145():187-205. PubMed ID: 26773870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge.
    Li B; Tesar D; Boswell CA; Cahaya HS; Wong A; Zhang J; Meng YG; Eigenbrot C; Pantua H; Diao J; Kapadia SB; Deng R; Kelley RF
    MAbs; 2014; 6(5):1255-64. PubMed ID: 25517310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
    Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
    Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?
    Gurbaxani B; Dostalek M; Gardner I
    Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.
    Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P
    J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.